January 2015 | OncologyLive

Complexities of Translating PD-1/PD-L1 Agents to Clinical Practice Emerge

January 20, 2015

As varying immunotherapy options become available for different types of cancers, researchers will have to take the next steps in clinical studies and in practice before the growing excitement over emerging agents can truly be translated into beneficial new therapies for patients.

Moving Beyond Targeted Therapy Stalwarts: Experts Weigh In on Four Tumor Types

January 19, 2015

OncologyLive asked experts in lymphoma, chronic myeloid leukemia, breast cancer, and non–small cell lung cancer to discuss the impact that the first targeted agents have had on these malignancies and the prospects for new therapeutic approaches.

13 Drugs to Watch in 2015

January 12, 2015

The FDA's calendar for making decisions on new oncology drugs and indications is taking shape for 2015, and the clock is ticking on at least 13 applications for novel agents and new therapeutic settings for existing drugs.

BRCA Pioneer Offit Shares Insights on Evolving Testing Landscape

January 07, 2015

For more than two decades, Kenneth Offit, MD, MPH, has been researching the molecular genetic factors that increase cancer risk, notably concerning germline BRCA mutations in breast and ovarian cancer, with a focus on potential preventive surgical remedies and screening programs for women at hereditary risk.

Effective Targeted Therapy Needed to Establish Clinical Utility of a Molecular Diagnostic Test

January 06, 2015

There has been considerable discussion and debate within the gynecologic oncology community for more than two decades regarding a role for second-look surgery (open or laparoscopic) in the management of advanced ovarian cancer.

West Describes Strategies for Personalizing NSCLC Therapy

January 05, 2015

A lung cancer researcher who has served on the editorial boards of major medical journals, Howard L. "Jack" West, MD, has made communicating with oncology specialists and patients a part of his professional mission.